The purpose of this study is to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge. A once weekly cluster regimen of 2 injections per visit was employed during the updosing phase, followed by monthly maintenance injections of 100,000 SQ units. Symptom scores, need of rescue medication were recorded by patients during the study period. The size of early and late cutaneous response to allergen challenge was recorded and measured by a physician.

Condition	Intervention	Phase
Seasonal Allergic Rhinoconjunctivitis	Vaccine: Sublingual Alutard SQ grass pollen tablets (Phleum pratense)  Procedure: Venepuncture: 100ml blood sample taken on 12 separate visits	Phase III

Further Study Details: 

Primary Outcomes: Symptom and medication score recorded by subjects; Adverse events
Secondary Outcomes: Rhinoconjunctivitis Quality of Life Questionnaire; Intradermal Allergen Challenge
Expected Total Enrollment:  18

This was a single centre, randomised, double-blind placebo controlled trial of grass pollen injection immunotherapy (Alutard SQ, ALK Abello, Denmark) in adults with severe summer hayfever unresponsive to antihistamines and topical steroids. The main aim was to determine at which point in the dosing regime grass pollen immunotherapy causes a significant reduction in the late skin response to allergen challenge. A once weekly cluster regimen of 2 injections per visit was employed during the updosing phase, followed by monthly maintenance injections of 100,000 SQ units. Twelve patients received active treatment (mean age 31, 7 male) whilst 6 were given placebo (mean age 37, 2 male). The 24 hour skin response (size of swelling, (mm)) to intradermal allergen challenge (0.1, 1, 10 BU) was determined on alternate weeks during the 8 week up-dosing phase and then monthly up to 6 months and 3 monthly up to 11-13 months following initiation of treatment. Results. At the end of the up-dosing phase (approximately 8 weeks) there was a significant reduction in the size of the late phase response which was evident with all three intradermal doses (p=0.02 for 0.1 & 1 BU and p=0.04 for 10 BU). This reduction was sustained throughout the maintenance phase (p=0.04 for 0.1 BU and 0.01 for 1& 10BU). Conclusion. The up-dosing phase of grass pollen immunotherapy alone is sufficient to dampen the late skin response to allergen challenge. Whether or not this may be predictive of the clinical response to immunotherapy remains to be determined.

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Male and female 18-65 years of age • Written informed consent obtained before entering the trial • A clinical history of grass pollen induced allergic rhinoconjunctivitis of two years or more requiring treatment during the grass pollen season • A clinical history of severe rhinoconjunctivitis symptoms (interfering with usual daily activities or sleep), which remain troublesome despite treatment with anti-allergic drugs during the grass pollen season • Positive Skin Prick Test (SPT) response (wheal diameter ≥ 3 mm) to Phleum pratense • Positive specific IgE against Phleum pratense (≥ IgE Class 2) • Physical examination with no clinically relevant findings • If pre-menopausal female of childbearing potential, the subject must test negative on standard urine pregnancy test and must be willing to practice appropriate contraceptive methods for the duration of the trial • Willingness to comply with this protocol

Exclusion Criteria:

• FEV1 < 70% of predicted value • A clinical history of symptomatic seasonal allergic rhinitis and/or asthma due to tree pollen or weed pollen adjacent to the start of – and potentially overlapping - the grass pollen season • A clinical history of significant symptomatic perennial allergic rhinitis and/or asthma caused by an allergen to which the subject is regularly exposed • A clinical history of significant recurrent acute sinusitis (defined as 2 episodes per year for the last two years all of which required antibiotic treatment) or chronic sinusitis • At randomisation, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process (serous otitis media is not an exclusion criterion) • History of emergency visit or admission for asthma in the previous 12 months • Use of an investigational drug within 30 days prior to screening • Previous treatment by immunotherapy with grass pollen allergen or any other allergen within the previous 5 years • History of anaphylaxis, including anaphylactic food allergy, bee venom anaphylaxis, exercise anaphylaxis or drug induced anaphylaxis • History of angioedema • Any of the following underlying conditions known or suspected to be present: Cystic fibrosis, malignancy, insulin-dependent diabetes, malabsorption or malnutrition, renal or hepatic insufficiency, chronic infection, drug dependency or alcoholism ischemic heart disease or angina requiring current daily medication or with any evidence of disease making implementation of the protocol or interpretation of the protocol results difficult or jeopardising the safety of the subject (e.g. clinically significant cardiovascular, serious immunopathologic, immunodeficiency whether acquired or not, hepatic, neurologic, psychiatric, endocrine, or other major systemic disease) • Immunosuppressive treatment • History of hypersensitivity to the excipients of the trial medications • History of allergy, hypersensitivity or intolerance to trial medications or rescue medications • A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude • Unlikely to be able to complete the trial, for any reason, or likely to travel for extended periods of time during the grass pollen season

United Kingdom
      Royal Brompton Hospital, NHLI Imperial College, London,  SW3 6LY,  United Kingdom

Study chairs or principal investigators

Stephen R Durham, Professor,  Principal Investigator,  Royal Brompton Hospital, Imperial College, National Heart & Lung Institute   

Study ID Numbers:  DHRG-UpDosing
Last Updated:  August 25, 2005
Record first received:  August 25, 2005
ClinicalTrials.gov Identifier:  NCT00135629
Health Authority: United Kingdom: Research Ethics Committee
ClinicalTrials.gov processed this record on 2005-09-13